{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=69&state=Alabama",
    "query": {
      "state": "Alabama",
      "city": "Birmingham",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 9523,
    "total_pages": 953,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=70&state=Alabama&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=68&state=Alabama&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T15:23:13.374Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02953509",
      "title": "Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Magrolimab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Allopurinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2016-11-21",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02953509"
    },
    {
      "nct_id": "NCT03061071",
      "title": "The POSAtive Study: Study for the Treatment of Positional Obstructive Sleep Apnea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sleep Apnea Syndromes"
      ],
      "interventions": [
        {
          "name": "NightBalance Sleep Position Trainer (SPT)",
          "type": "DEVICE"
        },
        {
          "name": "Automated Adjusting Positive Airway Pressure (APAP)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NightBalance",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "20 Years to 80 Years"
      },
      "enrollment_count": 117,
      "start_date": "2017-03-01",
      "completion_date": "2018-07-12",
      "has_results": false,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Gainesville, Florida + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03061071"
    },
    {
      "nct_id": "NCT02138734",
      "title": "A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "BCG (50mg/instillation) + N-803 (400 μg/instillation)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG (50mg/instillation)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 369,
      "start_date": "2014-07-21",
      "completion_date": "2039-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138734"
    },
    {
      "nct_id": "NCT03910244",
      "title": "Pomalidomide for the Treatment of Bleeding in HHT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Telangiectasia, Hereditary Hemorrhagic"
      ],
      "interventions": [
        {
          "name": "Pomalidomide Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2019-10-17",
      "completion_date": "2023-09-08",
      "has_results": true,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03910244"
    },
    {
      "nct_id": "NCT00101816",
      "title": "Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Blast Crisis"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2004-12",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2010-08-10",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101816"
    },
    {
      "nct_id": "NCT00401726",
      "title": "Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Venlafaxine ER",
          "type": "DRUG"
        },
        {
          "name": "Dialogues Time to Talk Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 537,
      "start_date": "2006-06",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2012-04-23",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401726"
    },
    {
      "nct_id": "NCT00002478",
      "title": "Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": null,
      "start_date": "1993-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-10",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002478"
    },
    {
      "nct_id": "NCT03199885",
      "title": "Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Adenocarcinoma",
        "Metastatic HER2-Positive Breast Carcinoma",
        "Recurrent Breast Adenocarcinoma",
        "Recurrent HER2-Positive Breast Carcinoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Unresectable Breast Carcinoma",
        "Unresectable HER2-Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2019-04-05",
      "completion_date": "2025-04-04",
      "has_results": true,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 662,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199885"
    },
    {
      "nct_id": "NCT05932615",
      "title": "ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aortic Valve Stenosis",
        "Heart Valve Diseases",
        "Aortic Valve Disease",
        "Heart Disease Structural Disorder"
      ],
      "interventions": [
        {
          "name": "Navitor Transcatheter Aortic Valve Implantation (TAVI) System",
          "type": "DEVICE"
        },
        {
          "name": "Any Commercially Available Transcatheter Aortic Valve (CAV) System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1500,
      "start_date": "2024-03-15",
      "completion_date": "2036-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fontana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05932615"
    },
    {
      "nct_id": "NCT00639158",
      "title": "Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemias",
        "Coronary Heart Disease",
        "Combined (Atherogenic) Dyslipidemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "ABT-335",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 543,
      "start_date": "2008-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-06-13",
      "last_synced_at": "2026-10-26T15:23:13.374Z",
      "location_count": 118,
      "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Hueytown",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00639158"
    }
  ]
}